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bstract
ackground:  Diffusion-weighted (DW)-MRI is invaluable in detecting prostate cancer. We determined its sensitivity and specificity and established
nterobserver agreement for detecting tumour in men with a family history of prostate cancer stratified by genetic risk.
ethods:  51 men with a family history of prostate cancer underwent T2-W + DW-endorectal MRI at 3.0 T. Presence of tumour was noted at right
nd left apex, mid and basal prostate sextants by 2 independent observers, 1 experienced and the other inexperienced in endorectal MRI. Sensitivity
nd specificity against a 10-core sampling technique (lateral and medial cores at each level considered together) in men with >2×  population risk
ased on 71 SNP analysis versus those with lower genetic risk scores was established. Interobserver agreement was determined at a subject level.
esults:  Biopsies indicated cancer in 28 sextants in 13/51 men; 32 of 51 men had twice the population risk (>0.25) based on 71 SNP profiling.
ensitivity/specificity per-subject for patients was 90.0%/86.4% (high-risk) vs. 66.7%/100% (low-risk, observer 1) and 60.0%/86.3% (high-risk) vs.
3.3%/93.8% (low-risk, observer 2) with moderate overall inter-observer agreement (kappa = 0.42). Regional sensitivities/specificities for high-risk
s. low-risk for observer 1 apex 72.2%/100% [33.3%/100%], mid 100%/93.1% [100%/97.3%], base 16.7%/98.3% [0%/100%] and for observer
 apex 36.4%/98.1% [0%/100%], mid 28.6%/96.5% [100%/100%], base 20%/100% [0%/97.3%] were poorer as they failed to detect multiple
esions.
onclusion:  Endorectal T2W + DW-MRI at 3.0 T yields high sensitivity and specificity for tumour detection by an experienced observer in
creening men with a family history of prostate cancer and increased genetic risk.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
icenses/by-nc-nd/3.0/).
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cho; TRUS, transrectal ultrasound.
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.  Introduction
Men with a strong family history of prostate cancer (defined
s a first degree relative with histologically or death certificate
roven prostate cancer diagnosed at <70 years or 2 relatives on
he same side of the family where at least one is diagnosed at <70
ears or ≥3 relatives on the same side of the family diagnosed
t any age) carry an increased risk of the disease compared to
he general population [1,2]. Seventy-six single nucleotide poly-
orphisms have been shown to be significantly associated with
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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rostate cancer in these men [3,4]. The detection of prostate
ancer in this population however, remains reliant on random,
on-targetted multiple biopsies of the gland, which are painful
nd carry a significant morbidity whilst not necessarily samp-
ing a relevant lesion. Diffusion-weighted MRI, when used in
onjunction with T2-W MRI has been shown to be sensitive at
etecting clinically significant prostate cancers [5] especially
hen random sampling in men with raised prostate specific
ntigen (PSA) is initially negative [6]. Moreover, the quantified
pparent diffusion coefficient (ADC), which reflects the water
iffusivity in the extracellular space, is increasingly restricted as
umours increase in cellularity [7] so that ADC correlates with
leason grade [8,9] and is invaluable in detecting significant
ancers. DW-MRI is easy to implement as a standard technique
n current MRI platforms, and an ADC map derived using scan-
er software can be visually assessed for the presence of tumour
s an area of restricted diffusion, as well as being quantifiable.
he purpose of this study therefore was to determine the sen-
itivity and specificity of T2W + DW-MRI as a screening tool
n men with a family history of prostate cancer stratified by
enetic risk and establish interobserver agreement for detecting
umour.
.  Methods
.1.  Subjects
This pilot diagnostic accuracy study had Institutional Review
oard approval and was performed as a single institution
tudy at a National Cancer Centre. Ethical standards com-
lied with the Helsinki Declaration of 1975 as revised in
013. Between January 2010 and July 2012, men aged 41–68
ears (mean 53.4 ±  8.5 years) with a positive family history
f prostate cancer defined as (i) one first degree relative with
istology or death-certificate proven prostate cancer at <70
ears, (ii) 2 relatives on the same side of the family with
rostate cancer where one is diagnosed at <70 years or (iii)
3 relatives on the same side of the family of any age,
ere invited into the study. Those with a previous cancer
nd with a terminal prognosis of <5 years or with a previ-
us diagnosis of prostate cancer but with a current negative
iopsy were excluded. Fifty-four patients were approached
o undergo MRI within this study: 2 declined because of
laustrophobia, the third had a high body mass index and
ad previously experienced discomfort being positioned in an
RI scanner, so declined. Fifty-one consecutive men willing
o undergo endorectal MRI followed by a 10-core transrec-
al ultrasound guided biopsy therefore were prospectively
ecruited. All subjects were imaged following written informed
onsent. PSA was 1.9 ±  1.7 ng/mL (mean ±  standard devia-
ion). The median interval between imaging and subsequent
iopsy was 15 days (lower quartile 6.5 days, upper quar-
ile 29 days). Although limited by the non-targetted approach
o biopsy, transrectal ultrasound guided random sampling of
he prostate remains the gold-standard for prostate cancer
iagnosis.
2
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.2.  SNP  analysis  and  scores
The participant’s DNA was genotyped on the iCOGS (Illu-
ina, Collaborative Oncological Gene-Environment Study)
hip. iCOGS is a custom Illumina iSelect genotyping array,
esigned to test genetic variants related to three hormone related
ancers of which prostate cancer is one [3]. Data was available
or 71 of the 76 previously identified known prostate cancer
usceptibility SNPs; 61 were directly genotyped and for 10
oci we used data for a proxy SNP with a linkage disequili-
rium >0.75 (3). The cumulative SNP risk score for each patient
as calculated by summing 71 risk alleles using the weighted
ffect (log-additive model) as estimated in previous studies [10].
atients were divided into those having a low risk (score <0.25)
r high risk (score ≥0.25), where 0.25 represented twice the
ifetime risk of 1 in 8 (0.125) in a normal population [11].
.3.  Imaging  methods
Images were acquired on a 3 T Philips Achieva (Best,
etherlands) using an endorectal coil (Medrad Inc., PA, USA) in
ombination with an external phased array coil. The endorectal
alloon was inflated with 60 ml of perfluorocarbon. Hyoscine
utyl bromide was administered routinely as an antiperistaltic
gent. T2-W images were obtained in 3 planes orthogonal to
he prostate (FSE, TR 2500 ms, TE 110 ms, FoV 14 cm, slice
hickness 2.2 mm, matrix 220 ×  184 extrapolated to 256 ×  256)
nd were complemented by diffusion weighted images in the
ransverse plane (single shot EPI, TR 5243 ms, TE 72 ms, b = 0,
00, 800 s/mm2, FOV 180 mm, slice thickness 2.2 mm, matrix
0 m ×  71 m, extrapolated to 128 ×  128). Whole pelvis imaging
as not deemed to be a requirement in this cohort.
.4.  Biopsy  procedure  and  histology  analysis
Ten cores were obtained using a random sampling technique
lateral and medial gland base, lateral and medial mid gland
nd apex from right and left lobes) under transrectal ultrasound
TRUS) guidance. The systematic biopsies were not formally
egistered to the MR data, although the MR images and reports
ere available to the operator performing the biopsies, so that
isual account could be taken of the position of any identified
esions. Routine antibiotic prophylaxis was administered with
iprofloxacin 500 mg twice daily and intrarectal Metronidazole
 g capsule 1–2 h prior to the procedure.
Sections obtained using 18-G Tru-cut needles were stained
ith haematoxylin and eosin and the presence or absence of
ancer and its Gleason grading were noted by a specialist
ropathologist. For the purposes of comparison with imaging the
ateral and medial cores at the base and mid gland of each side
ere scored together as either positive or negative for tumour.
.5.  Data  analysisApparent diffusion coefficient (ADC) maps were derived for
very voxel in the image using all b-values and a monoexpo-
ential fit of the data. Images were assessed by 2 observers; the
2 rnal of Radiology Open 1 (2014) 22–27
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Table 1
Sensitivity, specificity, by 2 independent observers for identifying tumour within
the prostate in a screening population at high risk.
Observer 1 risk score Observer 2 risk score
>0.25 <0.25 >0.25 <0.25
Whole prostate Sens% 90.0 66.7 60 33.3
Spec% 86.4 100 86.3 93.8
PPV% 75.0 100 66.7 50.0
NPV% 95.0 94.1 82.6 88.2
Apex Sens % 72.7 33.3 36.4 0
Sens% 100 100 98.1 100
Spec% 100 100 80.0 0
PPV% 94.6 94.6 88.1 92.1
Mid Sens% 100 100 28.6 100
Spec% 93.1 100 96.5 100
PPV% 60.0 100 50.0 100
NPV% 100 100 91.7 100
Base Sens% 16.7 0 16.7 0
Spec% 98.3 100 100 97.3
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rst had a considerable experience of endorectal imaging and of
eporting prostate imaging in a population managed by active
urveillance, the second was a dedicated uroradiologist with-
ut experience of endorectal MRI and did not have experience
f regular reporting a low-risk (Gleason 3 + 3) prostate can-
er population. The differences in observer performance were
eliberately addressed in order to understand how this technique
ight perform outside very specialist hands. The T2-W images,
iffusion-weighted images and ADC maps were viewed together
nd each sextant (superior third = basal, middle third = mid and
nferior third = apex for right and left sides) scored as positive
r negative for tumour by each observer independently. Tumour
as defined as a focal area of low signal-intensity within the
eripheral zone of the prostate that corresponded to an area
f restricted diffusion on the ADC map; in the central gland
f the prostate criteria included homogeneity of the focal low
ignal-intensity lesion with mass effect in order to exclude stro-
al nodules of benign prostatic hyperplasia. Sensitivity and
pecificity for identifying tumour within the prostate on a per-
ubject as well as on a per-sextant basis was determined for each
bserver. A kappa statistic was used to determine interobserver
greement.
All statistical tests used a value of less than 5% to denote
ignificance.
.  Results
No adverse events were experienced by any subject as a result
f endorectal MRI. Following biopsy, twenty eight sextants in
3/51 men were positive for tumour (1 sextant in 5 men, 2 in 5
en, 3 in 1 man, 4 in 1 man and 6 in 1 man). All lesions were
leason 3 + 3; percentage of tumour length to total core length
anged from 0.4% to 10% (median 1.6%). 32 of 51 patients had
umulative risk scores of >0.25 based on 71 SNPs. As biopsy
as performed after MRI in all cases, there was no artefact from
aemorrhage on imaging.
.1.  Per-subject  analysis
On MRI, lesions were sited in the peripheral zone in all but 1
ase where it was located across both peripheral zone and central
land. In the high-risk group, the incidence of positive biopsy
as 31.3% (10 of 32 cases), of which MRI detected 9 cases by
bserver 1 and 6 cases by observer 2. In the low-risk group, the
ncidence of positive biopsy was 15.8% (3 of 19 cases), of which
RI detected 2 cases by observer 1 and 1 case by observer 2.
ensitivity and specificity for each observer by group are given
n Table 1, and the Standards for the Reporting of Diagnostic
ccuracy Studies (STARD) flow chart is given in Fig. 1. For the
hole cohort at a per-subject level, agreement between observers
as moderate (kappa = 0.42).
.2.  Per-sextant  analysisIn the high-risk group 23 of 192 sextants were positive on his-
ology (12%) of which 15 were detected by observer 1 and 7 by
bserver 2. In the low-risk group 5 sextants of 114 (4.4%) were
[
w
w
sPPV% 50.0 0 100 0
NPV% 91.9 97.4 92.1 97.3
ositive on histology of which 2 were detected by observer 1 and
 by observer 2. Sensitivity and specificity for each observer on
 regional (apex, mid, base) basis is given in Table 1. For the 8
en with 2 or more sextants positive, observer 1 identified mul-
iple abnormal sextants in 5 cases, while observer 2 identified
ultiple abnormal sextants in 1 case only. A true positive case
s illustrated in Fig. 2 and a false positive case in Fig. 3.
.  Discussion
This study has indicated that TRUS random sampling biopsy
icked up prostate cancer in 31% of men with a family his-
ory of the disease stratified as high-risk (risk twice that of
ormal population) based on 71 SNP analysis and that DW-
RI by an experienced observer identified 90% of these with a
6% specificity. This is in keeping with previous data from an
ctive surveillance population where similar levels of sensitivity
nd specificity were recorded in a population all of whom had
revious positive biopsies [12]. As with the active surveillance
opulation, the sensitivity achieved is likely related to lesion size
nd Gleason grade as many of these cancers are of small size and
ow Gleason grade. The sensitivity of ADC as a biomarker has
een linked to Gleason grade [9] and ADC has been shown to be
ignificantly lower in aggressive disease [13]. Also the spatial
esolution of the technique used in this study, with a pixel size
f ∼6 mm2 meant that lesions of <3 contiguous pixels of low
DC (18 mm2) were unlikely to be recognised as tumour.
The difference in sensitivity and specificity between
bservers is also in line with previous data where lower sensitiv-
ty and specificity was observed with observers inexperienced
n low risk disease such as in an active surveillance population
12]. These data are in keeping with that from other studies,
here sensitivities and specificities improved from 54% to 81%
ith minimal loss of specificity (91–84% respectively) for Glea-
on 3 + 3 lesions of ∼4 mm by an experienced observer when
N.M. deSouza et al. / European Journal of Radiology Open 1 (2014) 22–27 25
Eligible paents n=54
MRI perf ormed n=51
Abn ormal result on MRI
n=12 [9]
Normal result on MRI
n=20 [23]
Abnormal result on MRI
n=2 [2]
Normal result on MRI n=17 
[17 ]
Genec risk >0.25 based on 71 
SNP proﬁling
Genec risk >0.25 based on 71 
SNP proﬁling
Histo Tumour 
present n=9 [6]
Histo Tumour 
absent n=3 [3]
Histo Tumour 
present n=1 [4]
Histo Tumour 
present n=2 [1]
Histo Tumour 
present n=1 [2]
Histo Tumour 
absent n=19  [19 ]
Histo Tumour 
absent n=0 [1]
Histo  Tumour absent 
n=16  [15 ]
Reference standar d tra nsr ectal ultrasoun d 10-core biopsy Reference standar d tra nsr ectal ultrasoun d 10-core biopsy
Fig. 1. STARD flow chart for index test (endorectal diffusion-weighted MRI at 3.0 T) for detecting tumour by observer 1 and observer 2 against a standard 10-core
random sampling transrectal ultrasound biopsy technique in men with a family history of prostate cancer stratified by genetic risk.
Fig. 2. True positive for prostate cancer in a 58 year old man: transverse T2-W images (FSE 2500/80 ms [TR/TE]) images (A) through the mid prostate obtained
with an endorectal coil at 3.0 T and corresponding ADC maps (B) generated from a monoexponential fit of diffusion-weighted data (EPI 8000/69 ms [TR/TE], b = 0,
100, 800 mm2/s). Outlines for whole prostate and central gland are given on the ADC maps. A lesion is not visible on the T2-W images, but a focally restricted area
on the ADC maps (arrow) corresponded to a positive biopsy from that sextant.
Fig. 3. False positive for prostate cancer in a 46 year old man: transverse T2-W images (FSE 2500/80 ms [TR/TE]) images (A) through the mid prostate obtained
with an endorectal coil at 3.0 T and corresponding ADC maps (B) generated from a monoexponential fit of diffusion-weighted data (EPI 8000/69 ms [TR/TE], b = 0,
100, 800 mm2/s). Outlines for whole prostate and central gland are given on the ADC maps. Although a lesion is not visible on the T2-W image, a small focally
restricted area on the ADC maps (arrow) was seen medially. However, all 12 biopsies from this subject were negative for tumour.
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WI was added to the T2W imaging [14]. Other multiobserver
tudies have similarly recorded a wide range in sensitivity and
pecificity: in a multireader (n  = 6) study, variation in these
arameters ranged from 26 to 51% and 47 to 72% respectively
15]. Although the reason for these variations has not been inter-
ogated, it is likely to relate to lesion size and the fact that subtle
ariations in ADC with lower Gleason grade tumours adversely
nfluence interpretation.
The sensitivity and specificity for detecting tumour at a sex-
ant level were poorer. Two factors are likely to have contributed
o this: firstly in patients with multiple tumours, MRI only iden-
ified one or some of the lesions. In 6 patients with multiple
esions, not all the lesions were identified on imaging. It is also
ossible that these were part of the same tumour, and so con-
iguous on MRI, whereas histology identified them on 2 separate
ores. It is possible that a multiparametric approach, for exam-
le the inclusion of DCE MRI may have improved this [16], but
he increased complexity in scan time, analysis time and cost
s not warranted in a screening setting. Secondly, definitions of
pex, mid and base are arbitrary and while we divided the gland
isually into “thirds” on MRI, this level of discrimination would
ot have been possible during transrectal biopsy sampling mak-
ng registration between adjacent sextants on MRI and histology
mperfect. Finally, the contrast between tumour and normal tis-
ue at the base of the prostate is reduced by the MR appearances
f the normal central zone, which classically has a much shorter
2 relaxation than the normal peripheral zone. This is due to its
nique histology comprising crowded tall columnar cells asso-
iated with thick muscle bundles at the bladder neck [17]. This
ay explain the lower sensitivity for recognizing tumour at the
land base.
This pilot study has some limitations. Most importantly, the
resence of cancer was based on 10 core TRUS biopsy which
ses a random sampling technique. Our negative cases may
herefore not have been truly negative had a more aggressive
ampling scheme such as template biopsy been considered. Tem-
late biopsies in healthy men in a screening context are poorly
cceptable to patients. They often necessitate a general anaes-
hetic and carry a significant morbidity, which is difficult to
ustify in a screening population. In the first instance, there-
ore we undertook a pilot study with TRUS biopsy to determine
hether we were able to pick up anything before a formal
tudy that incorporated template biopsy. Secondly, the diffusion-
eighted techniques employed although they used an endorectal
echnique at 3 T, could be improved by newer reduced field of
iew techniques such as zonal oblique multislice imaging [18]
hich allow much greater spatial resolution without significant
eduction in signal to noise ratio or increased acquisition time.
n a screening population where safety of the diagnostic inter-
ention is paramount, use of a technique that does not involve
onizing radiation or administration of a contrast agent is ideal.
t a very minimum 4 sequences would be required, bringing
can time down to 20 min; it is likely that future improvements
n scanner hardware and software reduce this further. However,
ost–benefit is also an issue and MRI although now widely avail-
ble incurs a significant financial burden. The restriction of its
se to those genetically stratified as being at high-risk or by af Radiology Open 1 (2014) 22–27
ombination of PSA and genetic risk will be of major impor-
ance in implementing this technique in a screening population.
n the first instance, establishing the robustness and accuracy in
 larger multicentre trial is warranted.
In summary, we have shown in a pilot study that T2W + DW-
RI is able to detect 90% of men with prostate cancer in a
creening population with a family history of the disease and a
2× population risk based on genetic profiling, but that experi-
nced observer interpretation is required. Improvements in the
rocess of automated analysis would advance this technique in
 larger population study, which are currently in the process of
etting up.
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